You are here

STTR Phase I: Microscope-based Technology For Automatic Brain Cell Counts Using Unbiased Methods

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1746511
Agency Tracking Number: 1746511
Amount: $224,417.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: BM
Solicitation Number: N/A
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-01-01
Award End Date (Contract End Date): 2018-12-31
Small Business Information
6260 Kipps Colony Court #304
Gulfport, FL 33707
United States
DUNS: 137488446
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Peter Mouton
 (410) 490-2034
Business Contact
 Peter Mouton
Phone: (410) 490-2034
Research Institution
 University of South Florida
 Dmitry Goldgof
 Nonprofit College or University

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is in automating the process of unbiased stereology, the state-of-the-method used in the life sciences for counting stained cells on tissue sections. Unbiased stereology allows neuroscientists to accurately analyze the size and number of brain cells, which are altered in many neurological disorders and mental illnesses. For reasons that are currently unknown, Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis are all associated with a progressive loss of brain cells. In contrast, children with autism are born with too many brain cells, which leads to life-long problems in processing complex streams of information. Stereology plays an important role in investigating many conditions affecting the brain and assessing the efficacy and safety of possible treatments. Though the proposed technology will initially target research studies to understand and treat all neurological conditions, it can be useful for automatic assessments of cells in all tissues, including cancer screening and diagnosis from biopsies. The proposed project will develop and optimize an algorithm to help brain scientists identify causes and treatments for neurological disease and mental illness. The proposed technology will use deep learning (artificial intelligence) systems to automatically recognize, count and size brain cells on tissue sections. An important use of this technology will be to analyze brains and nerve tissue from mice and rats treated to show similar neurological diseases as those found in humans. These animal models provide a powerful tool for testing treatments to cure brain disease in humans. Currently stereology studies of tissues from these animals require a trained technician to sit before a computer screen making tedious manual counts of hundreds and thousands of microscopic cells. This outdated approach fails to take advantage of powerful deep learning methods proposed for the proposed software that could complete these tasks 10 times faster and with fewer errors and human biases. Therefore, the proposed technology will use deep learning technology to accelerate basic research and drug development in the U.S., thereby establishing a long-term economic engine and bringing significant benefits to society through scientific breakthroughs and medical discoveries.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government